Stay updated with breaking news from Engitix Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Marc Lasry, the co-founder, chairman and chief executive of private-equity firm and hedge-fund investor Avenue Capital, has seen plenty of success in the sports world, as the Milwaukee Bucks he co-owns...
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology. Dr Gino Van Heeke, Engitix’s CSO said “We are delighted to have attracted a scientist as high calibre as Mike, who has the experience and expertise to help push forward our internal therapeutic projects as well as our partnered programmes...
Major Players: 95+ Key Companies Prominent Players: 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Akero Therapeutics Inc, Albireo Pharma Inc, Aldeyra Therapeutics Inc, Ascletis Pharma Inc, Zhejiang Doer Biologics Corp, Asdera LLC, Assembly Biosciences Inc, AstraZeneca Plc, Auransa Inc, Avaliv Therapeutics Inc, Avolynt Inc, ChemoCentryx Inc, ChemomAb Ltd, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, DURECT Corp, Eli Lilly and Co, Enanta Pharmaceuticals Inc EncuraGen Inc, Engitix Ltd, Hepion Pharmaceuticals Inc, Heprotech...